Newsletter: Q3 2012
Company News
Presentation at the CACO-PBS Bioanalytical Mini-Symposium
One of our scientists, Bruce Babson, gave a presentation on A Novel Approach to Internal Standardization in LC/MS/MS Analysis at the CACO-PBS Bioanalytical Mini-Symposium in August. It was a case study describing how we used a deuterium labeled derivatization reagent to make an ideal internal standard for Gentamicin, a complicated, multi-component drug substance for which no satisfactory internal standard was available.
View the presentation.
New LC/MS/MS System
We recently acquired, validated, and qualified an AB SCIEX API 4000 LC/MS/MS System, bringing our LC/MS/MS count to 15.
We occasionally receive requests from clients and prospective clients needing services that require specific equipment which we may not own. We carefully evaluate each of these requests and are often willing to acquire the new equipment necessary to meet their needs. The AB Sciex System was one of those instances. We received several inquiries from companies wanting to transfer their methods to MicroConstants exactly as written. To meet the needs of those clients, we decided to purchase the new system.
MicroConstants China’s New Facility Passes OECD GLP Compliance Inspection
In June, MicroConstants China’s new facility was visited by the Health Care Inspectorate, Ministry of Health, Welfare and Sport of Netherlands for an OECD GLP compliance reassessment. Following the week-long inspection, the Endorsement of Compliance was renewed and the Inspectorate confirmed the new facility is compliant with the OECD Principles of GLP in the areas of analytical chemistry and pharmacokinetic studies. Read the release.
MicroConstants China was originally awarded the endorsement in May of 2011 following an inspection at their previous location.
Upcoming Events & Poster Presentations
AAPS Annual Meeting & Exposition
We’ll be exhibiting at the AAPS Annual Meeting in Chicago, IL October 15 - 17, 2012. If you’re planning to attend, visit Gil Lam, David Yang, Ron Shevock, Ahmed Kousba, and Heather McMahon in Booth # 4927.
In addition to an exhibit booth, we will be presenting the following posters:
- Toxicokinetics of ETI-385 and its Components ETI 382 and ETI-383-A Serotonin 5 HT1A Receptor Agonist for Potential Treatment of Nausea and Vomiting, following Subcutaneous Injection of ETI-385 to CD-1 Mice and Beagle Dogs
- Toxicokinetics of CBX129801-A Bio-active C-peptide for Potential Replacement Therapy in Type 1 Diabetic Peripheral Neuropathy, following Subcutaneous Injection of CBX129801 in Rats in a 6 Month Study with a 7-week Recovery Period
- Toxicokinetics of CBX129801-A Bio-active C-peptide for Potential Replacement Therapy in Type 1 Diabetic Peripheral Neuropathy, following Subcutaneous Injection of CBX129801 in Monkeys in a 9 Month Study with a 7-week Recovery Period
North American Regional ISSX Meeting
Visit David Johnson, Mike Ly, and Rishi Sharma in Booth # 202 at the North American Regional ISSX Meeting October 14 - 17, 2012 in Dallas, TX.
We’re presenting a poster at this meeting as well. Use of Cold Compounds and High Resolution Mass Spectrometry to Quickly Characterize Drug Uptake in Cryopreserved Human Hepatocytes (Poster # P239) will be displayed during the meeting on Wednesday, 10/17 from 9:45 am – 4:30 pm.
Our AAPS and ISSX poster presentations will be available on our website immediately following the meetings.
Service Spotlight
Protein Binding Assays
Our We employ equilibrium dialysis, ultrafiltration, or ultracentrifugation techniques to determine the extent of binding to plasma, serum, or tissue proteins. Depending on your needs, we will perform submission-quality studies to generate protein binding data suitable for regulatory submissions, or screening assays to filter lead compounds and estimate protein binding values early in the discovery process. Read more.
<< Previous Issue | Back to Newsletters | Next Issue >>
